

Study Number: C13111-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA43: Hematology Summary

Test Compound: 2-(2H-Benzotriazol-2-yl)phenol

CAS Number: 10096-91-0

Date Report Requested: 08/06/2021

Time Report Requested: 08:29:01

Lab: Battelle

Study Number:

C13111-01

Study Sex:

Male

PWG Approval Date:

See web page for date of PWG Approval

Version:

v1.2.9

Stat Version:

2.1.1A

Study Number: C13111-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA43: Hematology Summary

Test Compound: 2-(2H-Benzotriazol-2-yl)phenol

CAS Number: 10096-91-0

Date Report Requested: 08/06/2021

Time Report Requested: 08:29:01

Lab: Battelle

Male					
		Treatment Groups (mg/kg)			
	Phase Day	0	30	100	300
Hematocrit (%)	SD 14	53.7 ± 1.2 (5)	52.7 ± 0.7 (5)	55.1 ± 1.1 (5)	53.8 ± 0.6 (5)
Percent of Control			98.2	102.8	100.3
Manual Hematocrit (%)	SD 14	50.4 ± 0.9 (5)	49.6 ± 0.2 (5)	51.4 ± 0.6 (5)	50.8 ± 0.6 (5)
Percent of Control			98.4	102.0	100.8
Hemoglobin (g/dL)	SD 14	16.4 ± 0.4 (5)	16.3 ± 0.2 (5)	17.0 ± 0.3 (5)	16.3 ± 0.2 (5)
Percent of Control			99.3	103.7	99.6
Erythrocytes (10 ⁶ /uL)	SD 14	9.20 ± 0.28 (5)	9.26 ± 0.22 (5)	9.49 ± 0.22 (5)	9.27 ± 0.07 (5)
Percent of Control			100.7	103.1	100.7
Reticulocytes (10 ³ /uL)	SD 14	233.6 ± 14.7 (5)	231.8 ± 12.5 (5)	298.6 ± 21.5 (5) *	279.1 ± 12.1 (5)
Percent of Control			99.2	127.8	119.5
Mean Cell Volume (fL)	SD 14	58.4 ± 0.7 (5)	57.0 ± 0.9 (5)	58.1 ± 0.4 (5)	58.0 ± 0.6 (5)
Percent of Control			97.6	99.6	99.4
Mean Cell Hemoglobin (pg)	SD 14	17.9 ± 0.1 (5)	17.6 ± 0.3 (5)	17.9 ± 0.1 (5)	17.6 ± 0.2 (5)
Percent of Control			98.4	100.1	98.7
Mean Cell Hemoglobin Concentration (g/dL)	SD 14	30.6 ± 0.2 (5)	30.9 ± 0.2 (5)	30.8 ± 0.2 (5)	30.4 ± 0.1 (5)
Percent of Control			100.9	100.7	99.3
Platelets (10 ³ /uL)	SD 14	858 ± 64 (5)	877 ± 52 (5)	774 ± 86 (5)	947 ± 68 (5)
Percent of Control			102.2	90.2	110.3
White Blood Cells (10 ³ /uL)	SD 14	13.46 ± 1.17 (5)	13.29 ± 0.95 (5)	13.36 ± 1.34 (5)	13.53 ± 1.26 (5)
Percent of Control			98.7	99.2	100.5
Neutrophils (10 ³ /uL)	SD 14	1.38 ± 0.16 (5)	1.29 ± 0.13 (5)	1.35 ± 0.29 (5)	1.24 ± 0.12 (5)
Percent of Control			93.8	97.8	89.7

Study Number: C131111-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA43: Hematology Summary

Test Compound: 2-(2H-Benzotriazol-2-yl)phenol

CAS Number: 10096-91-0

Date Report Requested: 08/06/2021

Time Report Requested: 08:29:01

Lab: Battelle

Male

		Treatment Groups (mg/kg)							
		0		30		100		300	
Phase Day									
Lymphocytes (10 ³ /uL)	SD 14	11.46 ±	0.96 (5)	11.30 ±	0.85 (5)	11.30 ±	1.00 (5)	11.68 ±	1.06 (5)
Percent of Control				98.6		98.6		101.8	
Monocytes (10 ³ /uL)	SD 14	0.33 ±	0.04 (5)	0.40 ±	0.06 (5)	0.35 ±	0.06 (5)	0.34 ±	0.05 (5)
Percent of Control				122.6		107.9		103.7	
Basophils (10 ³ /uL)	SD 14	0.08 ±	0.01 (5)	0.09 ±	0.01 (5)	0.11 ±	0.03 (5)	0.08 ±	0.02 (5)
Percent of Control				112.5		135.0		105.0	
Eosinophils (10 ³ /uL)	SD 14	0.09 ±	0.02 (5)	0.09 ±	0.03 (5)	0.13 ±	0.04 (5)	0.07 ±	0.01 (5)
Percent of Control				97.9		136.2		76.6	
Large Unstained Cells (10 ³ /uL)	SD 14	0.12 ±	0.02 (5)	0.11 ±	0.01 (5)	0.12 ±	0.04 (5)	0.12 ±	0.03 (5)
Percent of Control				89.8		101.7		105.1	

Study Number: C13111-01**Test Type:** TOX**Route:** Oral Gavage**Species/Strain:** Rat/Harlan Sprague Dawley**PA43: Hematology Summary****Test Compound:** 2-(2H-Benzotriazol-2-yl)phenol**CAS Number:** 10096-91-0**Date Report Requested:** 08/06/2021**Time Report Requested:** 08:29:01**Lab:** Battelle

Male

		Treatment Groups		
	Phase Day	1000		
Hematocrit (%)	SD 14	52.0	± 0.9	(5)
Percent of Control		96.9		
Manual Hematocrit (%)	SD 14	48.2	± 0.6	(5)
Percent of Control		95.6		
Hemoglobin (g/dL)	SD 14	15.8	± 0.2	(5)
Percent of Control		96.5		
Erythrocytes (10 ⁶ /uL)	SD 14	9.01	± 0.21	(5)
Percent of Control		97.8		
Reticulocytes (10 ³ /uL)	SD 14	236.7	± 7.3	(5)
Percent of Control		101.3		
Mean Cell Volume (fL)	SD 14	57.8	± 0.9	(5)
Percent of Control		99.0		
Mean Cell Hemoglobin (pg)	SD 14	17.6	± 0.3	(5)
Percent of Control		98.3		
Mean Cell Hemoglobin Concentration (g/dL)	SD 14	30.4	± 0.2	(5)
Percent of Control		99.4		
Platelets (10 ³ /uL)	SD 14	1001	± 30	(5)
Percent of Control		116.6		
White Blood Cells (10 ³ /uL)	SD 14	12.02	± 0.76	(5)
Percent of Control		89.3		
Neutrophils (10 ³ /uL)	SD 14	1.17	± 0.11	(5)
Percent of Control		84.5		

Study Number: C131111-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA43: Hematology Summary

Test Compound: 2-(2H-Benzotriazol-2-yl)phenol

CAS Number: 10096-91-0

Date Report Requested: 08/06/2021

Time Report Requested: 08:29:01

Lab: Battelle

Male

	Phase Day	Treatment Groups
		1000
Lymphocytes (10 ³ /uL)	SD 14	10.32 ± 0.64 (5)
Percent of Control		90.0
Monocytes (10 ³ /uL)	SD 14	0.30 ± 0.08 (5)
Percent of Control		92.7
Basophils (10 ³ /uL)	SD 14	0.07 ± 0.01 (5)
Percent of Control		82.5
Eosinophils (10 ³ /uL)	SD 14	0.07 ± 0.01 (5)
Percent of Control		70.2
Large Unstained Cells (10 ³ /uL)	SD 14	0.09 ± 0.02 (5)
Percent of Control		79.7

Study Number: C131111-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

PA43: Hematology Summary

Test Compound: 2-(2H-Benzotriazol-2-yl)phenol

CAS Number: 10096-91-0

Date Report Requested: 08/06/2021

Time Report Requested: 08:29:01

Lab: Battelle

LEGEND

Values given as mean $\pm$ SEM (N) with Percent of Control calculated by (dosed group mean / control group mean) x 100

SD – Study Day

Statistical analysis was performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

* Statistically significant at $P \leq 0.05$

** Statistically significant at $P \leq 0.01$

**** END OF REPORT ****